{{Drugbox
| IUPAC_name = 7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
| image = Flubromazepam.svg
| width = 222

<!--Clinical data-->
| legal_CA = Schedule IV
| legal_DE = Anlage II
| legal_US = Unscheduled 
| legal_US_comment = (Virginia, Schedule I)
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 106 hours
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 2647-50-9
| PubChem = 12947024
| ChemSpiderID = 10441497
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = GKX573279U

<!--Chemical data-->
| C=15 | H=10 | Br=1 | F=1 | N=2 | O=1
| molecular_weight = 333.16 g/mol
| smiles = BrC1=CC(C(C2=CC=CC=C2F)=NC3)=C(C=C1)NC3=O
| StdInChI = 1S/C15H10BrFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)
| StdInChIKey = ZRKDDZBVSZLOFS-UHFFFAOYSA-N
}}

'''Flubromazepam''' is a [[benzodiazepine]] derivative which was first synthesized in 1960,<ref>{{cite patent | country = US | number = 3136815 | title = Amino substituted benzophenone oximes and derivatives thereof}}</ref> but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a novel [[designer drug]].<ref name="Moosmann">{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/jms.3279/abstract | title=Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics | date=November 2013 |author1=Bjoern Moosmann |author2=Laura M. Huppertz |author3=Melanie Hutter |author4=Armin Buchwald |author5=Sascha Ferlaino |author6=Volker Auwärter | journal=Journal of Mass Spectrometry | volume=48 | issue=11 | pages=1150–1159 | doi=10.1002/jms.3279 | pmid=24259203}}</ref><ref>{{cite web | url=https://www.uniklinik-freiburg.de/fileadmin/mediapool/08_institute/rechtsmedizin/pdf/Poster2013/Moosmann_DesignerBenzodiazepine_TIAFT2013.pdf | title=Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples | publisher=Institute of Forensic Medicine, Forensic Toxicology, University Medical Center Freiburg, Freiburg, Germany |author1=B. Moosmann |author2=M. Hutter |author3=L. M. Huppertz |author4=V. Auwärter }}</ref><ref>{{cite journal | author1=Lauren C. O'Connor | url=http://jat.oxfordjournals.org/content/40/2/159 | title=ELISA Detection of Phenazepam, Etizolam, Pyrazolam, Flubromazepam, Diclazepam and Delorazepam in Blood Using Immunalysis® Benzodiazepine Kit | author2=Hazel J. Torrance | author3=Denise A. McKeown | journal=Journal of Analytical Toxicology | year=March 2016 | volume=40 | issue=2 | pages=159–161 | doi=10.1093/jat/bkv122 | pmid=26518230}}</ref><ref>{{cite web | url=http://nsddb.eu/substance/375/ | title=Flubromazepam | publisher=New Synthetic Drugs Database}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.2003/abstract | title=Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays |author1=Madeleine Pettersson Bergstrand |author2=Anders Helander |author3=Therese Hansson |author4=Olof Beck | journal=Drug Testing and Analysis | date=2016 | doi=10.1002/dta.2003 | pmid=27366870}}</ref><ref>{{cite journal|first1=Gudrun|last1=Høiseth|first2=Silja Skogstad|last2=Tuv|first3=Ritva|last3=Karinen|title=Blood concentrations of new designer benzodiazepines in forensic cases|url=http://www.sciencedirect.com/science/article/pii/S0379073816304121|journal=Forensic Science International|doi=10.1016/j.forsciint.2016.09.006|date=2016|volume=268|pages=35–38|pmid=27685473}}</ref>

It is a [[structural analog]] of [[phenazepam]] in which the chlorine atom has been replaced by a fluorine atom.

An alternate isomer, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2''H''-1,4-benzodiazepin-2-one or "iso-flubromazepam",<ref>Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. ''Therapeutic Advances in Psychopharmacology''. 2015;5(2):97-132. doi:10.1177/2045125314559539.</ref> may have been sold under the same name.<ref name="Moosmann"/>

[[Image:Flubromazepam isomer.svg|200px|thumb|left|Alternate isomer]]

== Legal status ==

=== United Kingdom ===

In the UK, flubromazepam has been classified as a [[Drugs controlled by the UK Misuse of Drugs Act|Class C drug]] by the May 2017 amendment to [[Misuse of Drugs Act 1971|The Misuse of Drugs Act 1971]] along with several other designer benzodiazepine drugs.<ref>{{Cite web|url=http://www.legislation.gov.uk/uksi/2017/634/contents/made|title=The Misuse of Drugs Act 1971 (Amendment) Order 2017|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

=== United States ===

Clonazolam, Flubromazepam, Flubromazolam have now all been placed into Schedule I under Virginia State Law.<ref>{{Cite web|url=http://law.lis.virginia.gov/admincode/title18/agency110/chapter20/section322/}}</ref>

==See also==
{{Colbegin}}
* [[List of benzodiazepine designer drugs]]
* [[Desmethyletizolam]]
* [[Imidazenil]] (licensed)
* [[Phenazepam]]
{{colend}}

==References==
{{Reflist|2}}

{{Benzodiazepines}}

[[Category:Benzodiazepines]]
[[Category:Bromoarenes]]
[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Hypnotics]]


{{sedative-stub}}